Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M88.0Revenue (TTM) $M--Net Margin (%)--Altman Z-Score-3.2
Enterprise Value $M35.7EPS (TTM) $-2.3Operating Margin %--Piotroski F-Score3
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yY
Price/Book1.710-y EBITDA Growth Rate %--Quick Ratio9.7Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio9.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-61.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-73.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M23.8ROIC % (ttm)-933.6Gross Margin Increase y-yN

Gurus Latest Trades with LIFE

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

LIFE is held by these investors:



LIFE: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MENDLEIN JOHNCEO and Director 2017-04-24Buy124$322.67view
MENDLEIN JOHNCEO and Director 2017-04-20Buy2,552$322.67view
SCHIMMEL PAULDirector 2016-12-21Buy25,000$2.2861.4view
Amanullah AshrafVice President, Manufacturing 2016-12-20Buy11,000$2.2563.56view
MENDLEIN JOHNCEO and Director 2016-12-19Buy69,000$2.267.27view
SCHIMMEL PAULDirector 2016-12-16Buy50,000$2.4848.39view
Matsuoka GroveSee Remarks 2016-05-11Buy12,412$3.0421.05view
SCHIMMEL PAULDirector 2016-04-14Buy66,219$4.18-11.96view
SCHIMMEL PAULDirector 2016-04-13Buy9,835$3.85-4.42view
SCHIMMEL PAULDirector 2016-04-12Buy9,127$3.71-0.81view

Press Releases about LIFE :

Quarterly/Annual Reports about LIFE:

News about LIFE:

Articles On GuruFocus.com
aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the Amer May 15 2017 
aTyr Pharma Announces First Quarter 2017 Operating Results May 11 2017 
aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dy Apr 24 2017 
aTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in P Apr 24 2017 
aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors Apr 10 2017 
aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors Apr 03 2017 
PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Va Apr 01 2016 

More From Other Websites
aTyr Pharma to Present at Jefferies 2017 Global Healthcare Conference May 31 2017
aTyr Pharma Announces Presentations on Interstitial Lung Disease and the iMod.Fc Program at the... May 15 2017
Atyr Pharma reports 1Q loss May 11 2017
aTyr Pharma Announces First Quarter 2017 Operating Results May 11 2017
aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular... Apr 24 2017
aTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in... Apr 24 2017
aTyr Pharma Announces Appointment of Timothy P. Coughlin to its Board of Directors Apr 10 2017
aTyr Pharma Announces Appointment of Jeffery S. Hatfield to its Board of Directors Apr 03 2017
aTyr Pharma to Present at Needham and Company 16th Annual Healthcare Conference Mar 29 2017
aTyr Pharma Announces Issuance of US Patent That Extends Patent Protection of Physiocrines Derived... Mar 15 2017
aTyr Pharma Receives EMA Orphan Drug Designation for the Treatment of Limb Girdle Muscular Dystrophy... Mar 03 2017
aTyr Pharma Rises 16% on Orphan Drug Status Mar 01 2017
aTyr Pharma to Present at Cowen and Company 37th Annual Health Care Conference Mar 01 2017
aTyr Pharma Receives U.S. FDA Orphan Drug Designation for the Treatment of Limb Girdle Muscular... Feb 28 2017
High court ruling limits international reach of patent laws Feb 22 2017
Atyr Pharma Stock Spikes 33% on FDA Updates Jan 19 2017
FDA Grants Fast Track Designation for aTyr's Resolaris™ to Treat Limb Girdle Muscular Dystrophy 2B... Jan 18 2017
Roberts recuses from patent case after discovering conflict Jan 04 2017
Atyr Pharma Inc (LIFE) CEO and Director John Mendlein Bought $151,800 of Shares Dec 21 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}